Choose Mounjaro for Appropriate Adult Patients With T2D

Engage directly with a highly regarded peer about how once-weekly Mounjaro may help your adult patients with T2D. In this program you will learn about: Once-weekly Mounjaro-the first and only GIP and GLP-1 receptor agonist indicated to improve glycemic control in adults with T2D¹ The clinical efficacy and safety of Mounjaro How to support patients starting and staying on Mounjaro

Program Objectives Understand the importance of A1C and weight in T2D management Differentiate the mechanism of action of Mounjaro from that of other T2D treatments Highlight key clinical efficacy and safety results with Mounjaro, including change in A1C and, as a key secondary endpoint, change in body weight¹ Review how to help patients start and stay on Mounjaro